Verici Dx PLC (AIM:VRCI) shares were up as much as 11% in early trading after the diagnostics company announced it had successfully completed its second biennial inspection by the College of American Pathologists (CAP), one of the leading US bodies for clinical laboratory accreditation.
The inspection passed with no deficiencies, confirming the company’s continued compliance with CAP’s rigorous quality and operational standards. Maintaining this accreditation is essential for laboratories providing clinical diagnostic testing in the United States.
Verici Dx said the result demonstrates its ongoing commitment to laboratory excellence and its ability to deliver consistent, reliable results under a robust quality management system.
Dave Schultenover, vice-president of quality and regulatory affairs, said the company “values the clinicians and patients that put their trust in our clinical laboratory” and remains “dedicated to continuing to meet or exceed regulatory requirements to be a trusted partner to clinicians.”
After the initial early burst, the stock settled at 0.89p, up 4%.